In the News
The Burrill Report interviews Greg Scott on WuXi/CRL breakup and China's hot IPOs
 
Greg Scott joined Foley's Eye on China webinar on life science innovation
>>Foley webinar...
Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

>> Preview...

SFDA Approves China Medical’s HER2 FISH Probe

publication date: Nov 12, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

China Medical Technologies (中国医疗技术公司) received SFDA approval for its Breast Cancer HER2 FISH probe. Breast cancer patients are routinely tested for overexpression of HER2 protein because overexpression is associated with a higher incidence of recurrence and also predicts a better response to Genentech’s breast cancer drug, Herceptin. More details...

Stock Symbols: (NSDQ: CMED) (NYSE: DNA)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events
BioBay Investor Forum 2010
Suzhou, China
November 3 - 4, 2010
China Forum 2010
Munich, Germany
November 14, 2010

 
ChinaBio® Investor Forum 2010 - Guangzhou
Guangzhou, China
December 21, 2010
Partner Events
BioPharm America™ 2010
Boston, MA, USA
September 15–17, 2010

CALAsia 2010
San Diego, USA
October 4-5, 2010

CHINA PRETRIALS 2010: Global Preclinical Development Summit
Beijing, China
October 17-19, 2010

CHINA TRIALS 2010
Beijing, China
November 7-9, 2010

12th Shanghai International Forum on Biotechnology & Pharmaceutical Industry (BIO-FORUM)
Beijing, China
November 9-11, 2010
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners